Evidence map›Paper›PMID 40204600›Full record

ArticleEuropean urology2025

Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [

Andrew J Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J Krause, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Fred Saad and 4 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in European urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Andrew J ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Departments of Medicine, Surgery, Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Oliver SartorDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Johann de BonoThe Institute of Cancer Research and The Royal Marsden Hospital, London, UK.
Kim ChiDivision of Medical Oncology, University of British Columbia, Vancouver, BC, Canada.
Karim FizaziCancer Medicine Department, Gustave Roussy Institute, University of Paris Saclay, Villejuif, France.
Bernd J KrauseDepartment of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany.
Ken HerrmannClinic for Nuclear Medicine, University Hospital Essen, Essen, Germany.
Kambiz RahbarDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Scott T TagawaDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Fred SaadUrology Department, University of Montreal Hospital Center, University of Montreal, Montreal, QC, Canada.
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jiwen WuNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Osvaldo MiranteAdvanced Accelerator Applications, a Novartis company, Geneva, Switzerland.
Michael J MorrisGenitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: morrism@mskcc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40204600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.